JP2024515770A5 - - Google Patents
Info
- Publication number
- JP2024515770A5 JP2024515770A5 JP2023565586A JP2023565586A JP2024515770A5 JP 2024515770 A5 JP2024515770 A5 JP 2024515770A5 JP 2023565586 A JP2023565586 A JP 2023565586A JP 2023565586 A JP2023565586 A JP 2023565586A JP 2024515770 A5 JP2024515770 A5 JP 2024515770A5
- Authority
- JP
- Japan
- Prior art keywords
- benzoxazole
- dichlorophenyl
- carboxylic acid
- crystalline
- producing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21382362.8 | 2021-04-26 | ||
| EP21382362.8A EP4083027A1 (en) | 2021-04-26 | 2021-04-26 | A solid state form of tafamidis and a process for its preparation |
| PCT/EP2022/060716 WO2022229026A1 (en) | 2021-04-26 | 2022-04-22 | A solid state form of tafamidis and a process for its preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024515770A JP2024515770A (ja) | 2024-04-10 |
| JP2024515770A5 true JP2024515770A5 (https=) | 2025-03-10 |
Family
ID=75746555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023565586A Pending JP2024515770A (ja) | 2021-04-26 | 2022-04-22 | タファミジスの固体形態及びその製造方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20240208915A1 (https=) |
| EP (2) | EP4083027A1 (https=) |
| JP (1) | JP2024515770A (https=) |
| CN (1) | CN117255781A (https=) |
| BR (1) | BR112023022116A2 (https=) |
| CA (1) | CA3216325A1 (https=) |
| MX (1) | MX2023012460A (https=) |
| WO (1) | WO2022229026A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250042864A1 (en) * | 2021-11-17 | 2025-02-06 | Teva Pharmaceuticals International Gmbh | Solid state form of tafamidis |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2800237C (en) | 2002-12-19 | 2016-05-17 | The Scripps Research Institute | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
| RU2565066C2 (ru) * | 2010-04-21 | 2015-10-20 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Производные 1-(2-фторбифенил-4-ил)-алкилкарбоновой кислоты для лечения транстиретинового амилоидоза |
| RU2586330C2 (ru) | 2011-09-16 | 2016-06-10 | Пфайзер Инк. | Твердые формы ингибитора диссоциации транстиретина |
| PT4349406T (pt) | 2014-09-08 | 2026-02-04 | Pfizer | Formas sólidas cristalinas de 6-carboxi-2-(3,5-diclorofenil)-benzoxazol para utilização como medicamento |
| GB2571950A (en) | 2018-03-13 | 2019-09-18 | Azad Pharma Ag | New polymorph and new path to synthesize tafamidis |
| EP3969443B1 (en) | 2019-05-16 | 2024-11-20 | Teva Pharmaceuticals International GmbH | Solid state forms of tafamidis and salts thereof |
| US20220251052A1 (en) * | 2019-07-04 | 2022-08-11 | Msn Laboratories Private Limited, R&D Center | Improved process for the preparation of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid or its pharmaceutically acceptable salts and polymorphs thereof |
| WO2021019448A1 (en) | 2019-08-01 | 2021-02-04 | Honour (R&D) | Process for the preparation of transthyretin dissociation inhibitor |
| WO2021152623A1 (en) * | 2020-01-27 | 2021-08-05 | Dr. Reddy’S Laboratories Limited | Improved processes for the preparation of tafamidis and its meglumine salt |
| US12522573B2 (en) * | 2020-10-19 | 2026-01-13 | Alivus Life Sciences Limited | Process for preparation of tafamidis and salts thereof |
-
2021
- 2021-04-26 EP EP21382362.8A patent/EP4083027A1/en not_active Withdrawn
-
2022
- 2022-04-22 JP JP2023565586A patent/JP2024515770A/ja active Pending
- 2022-04-22 CA CA3216325A patent/CA3216325A1/en active Pending
- 2022-04-22 US US18/288,195 patent/US20240208915A1/en active Pending
- 2022-04-22 WO PCT/EP2022/060716 patent/WO2022229026A1/en not_active Ceased
- 2022-04-22 MX MX2023012460A patent/MX2023012460A/es unknown
- 2022-04-22 CN CN202280030391.4A patent/CN117255781A/zh active Pending
- 2022-04-22 BR BR112023022116A patent/BR112023022116A2/pt unknown
- 2022-04-22 EP EP22724736.8A patent/EP4330237A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI847144B (zh) | 奧美卡替莫卡必爾的合成 | |
| JP2023519891A5 (https=) | ||
| CA2410234C (en) | 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl in pure crystalline form and process for synthesis | |
| JP2005509025A5 (https=) | ||
| CN103539795A (zh) | 阿哌沙班的多晶型及其制备方法 | |
| JP2015107976A (ja) | 結晶形態のテノホビルジソプロキシル及びその製造方法 | |
| AU2001264804A1 (en) | 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- [2,3']bipyridinyl in pure crystalline form and process for synthesis | |
| JP2024537795A5 (https=) | ||
| JP2009521414A5 (https=) | ||
| JP2024100792A5 (https=) | ||
| JP2024515770A5 (https=) | ||
| JP2025148397A5 (https=) | ||
| JP2024521412A5 (https=) | ||
| JP2024514090A5 (https=) | ||
| JP6068569B2 (ja) | シロドシンの製造方法および中間体 | |
| JP2022542803A5 (https=) | ||
| CZ1494A3 (en) | Process for preparing diphenyl derivatives, aromatic compound and its use | |
| JP2022540678A5 (https=) | ||
| CA2447878C (en) | 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl in pure crystalline form and process for synthesis | |
| JPS61167673A (ja) | （イソキサゾール‐３‐イル）アリールメタノンおよびその製造方法 | |
| EP2385046B1 (fr) | Phase précurseur et son utilisation pour préparer le sel de magnésium tétrahydraté d'un énantiomère d'oméprazole | |
| JP2024529763A5 (https=) | ||
| JPH08507299A (ja) | ヒドロキシメチルフラザンカルボン酸誘導体及びこれを心臓血管系疾患の治療に使用する方法 | |
| KR20240038023A (ko) | 식 i의 화합물의 결정형 및 이의 제조와 응용 | |
| JP2023523165A5 (https=) |